Altruist Biologics

As biopharma companies increasingly seek to optimize the drug development timeline, China has emerged as a cost-effective biomanufacturing hub for both the rapidly growing Chinese market and the rest of the world. New localization guidelines set by the NMPA’s Center for Drug Evaluation encourage global companies to adopt a “China for China” manufacturing strategy for maximum commercial value creation. Achieving seamless drug production in China requires a strong partnership with an established CDMO who can help navigate China’s complex regulatory landscape and expedite the commercialization process. This session will explore the regulatory guidelines for localization as well as the key attributes global biopharma companies should look for in a reliable partner who can help leverage the opportunities and avoid the pitfalls to deliver quality outcomes.